Daria I. Lagutina

Daria I. Lagutina

Auto-generated profile, based on publicly available information

Daria I. Lagutina

Almazov National Medical Research Centre

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
TKTatiana Karonova
Tatiana Karonova
KGKsenia Golovatyuk
Ksenia Golovatyuk
Igor KudryavtsevIgor Kudryavtsev
Igor Kudryavtsev
AAAlena Andreeva
Alena Andreeva
AMArina Mikhaylova
Arina Mikhaylova
ESEvgeny V. Shlyakhto
Evgeny V. Shlyakhto
Recent studies showed that a low 25-hydroxyvitamin D (25(OH)D) level was associated with a higher risk of morbidity and severe course of COVID-19. Our study aimed to evaluate the effects of cholecalciferol supplementation on the clinical features and inflammatory markers in patients with COVID-19. A serum 25(OH)D level was determined in 311 COVID-19 patients. Among them, 129 patients were then randomized into two groups with similar concomitant medication. Group I (n = 56) received a bolus of cholecalciferol at a dose of 50,000 IU on the first and the eighth days of hospitalization. Patients from Group II (n = 54) did not receive the supplementation. We found significant differences between groups with the preferential increase in serum 25(OH)D level and Δ 25(OH)D in Group I on the ninth day of hospitalization (p < 0.001). The serum 25(OH)D level on the ninth day was negatively associated with the number of bed days (r = −0.23, p = 0.006); we did not observe other clinical benefits in patients receiving an oral bolus of cholecalciferol. Moreover, in Group I, neutrophil and lymphocyte counts were significantly higher (p = 0.04; p = 0.02), while the C-reactive protein level was significantly lower on the ninth day of hospitalization (p = 0.02). Patients with supplementation of 100,000 IU of cholecalciferol, compared to those without supplementation, showed a decrease in the frequencies of CD38++CD27 transitional and CD27−CD38+ mature naive B cells (p = 0.006 and p = 0.02) and an increase in the level of CD27−CD38− DN B cells (p = 0.02). Thus, the rise in serum 25(OH)D level caused by vitamin D supplementation in vitamin D insufficient and deficient patients may positively affect immune status and hence the course of COVID-19.

13 November 2023 in Diabetes mellitus
Verified
Journal Article
Open access
PDF file
TKTatiana Karonova
Tatiana Karonova
AMArina Mikhaylova
Arina Mikhaylova
DLD. I. Lagutina
D. I. Lagutina
ОВО. М. Воробьева
О. М. Воробьева
ДГД. О. Григорьева
Д. О. Григорьева
ESE. V. Shlyakhto
E. V. Shlyakhto
BACKGROUND. Glucose metabolism disorders (GMD) were detected both in acute and in post-COVID, however, its pathogenic aspects remain unclear.AIM. To analyze the occurrence of GMD in post-COVID patients who have had moderate and severe COVID-19 without previously known GMD disorders, and evaluate expression of SARS-CoV-2 proteins and its entry factors in pancreas in acute COVID-19.METHODS. Among 187 hospitalized patients with confirmed COVID-19 141 patients without previously diagnosed GMD underwent follow-up post-COVID visits. The examination for all patients included anthropometric measurement with calculation of BMI, level of HbA1c and fasting plasma glucose, for 106 patients level of insulin and HOMA-IR index was analyzed. For histological examination, pancreas fragments of 20 patients with fatal outcome were selected. Immunohistochemical study was performed with antibodies to SARS-CoV-2, ACE2, DPP4, as well as double-labeled immunofluorescence microscopy (insulin-SARS-CoV-2, insulin-ACE2, insulin-DPP4).RESULTS. Among 141 patients in post-COVID period, 9 (6.3%) had HbA1c or fasting plasma glucose levels that met criteria for diabetes mellitus, 38 (26.9%) — exceeded normal values (WHO), and 84 (59.6%) had GMD according to criteria of the ADA. In post-COVID, patients with GMD had a higher BMI and HOMA-IR index (p=0.001) compared to patients with normal glycemic levels. Only 40.4% of people had HOMA-IR index above 2.7. Patients with GMD had higher level of CRP (p=0.007) and a maximum glucose level (p=0.019) in the acute period. Positive relationship was found between BMI and HOMA index both in acute (p<0.001; r=0.389) and post-COVID (p<0.001; r=0.412) periods, as well as the level of HbA1c in acute period (p=0.019, r=0.202) and in post-COVID (p=0.004, r=0.242).Histological and immunohistochemical studies showed the expression of SARS-CoV-2 proteins in 1.85% [0–15.4] and 11.1% [5.3–14.8] cells of the Langerhans islets in patients who died on the second and third waves, respectively. The expression of ACE2 and DPP4 in the islets of Langerhans did not exceed 0.4% [0–1.7] and 0.5% [0–0.8] of cells, respectively. Double-labeled immunofluorescence microscopy showed co-localization of SARS-CoV-2, ACE2, DPP4 with insulin.CONCLUSION. Post-COVID Glucose metabolism disorders may be explained by direct cytotoxic effect of SARS-COV-2, increased glucose toxicity and insulin resistance because of the acute infection and its complex therapy.

13 October 2023 in Journal Infectology
Verified
Journal Article
Open access
PDF file
TKTatiana Karonova
Tatiana Karonova
IKI. N. Korsakov
I. N. Korsakov
AMArina Mikhaylova
Arina Mikhaylova
DLD. I. Lagutina
D. I. Lagutina
AAAlena Andreeva
Alena Andreeva
ESE. V. Shlyakhto
E. V. Shlyakhto
Aim. To create algorithm and risk calculator for predicting the lethal outcome in patients with COVID-19.Materials and methods. Based on machine learning approach mortality risk calculator was developed in Almazov National Medical Research Centre using data of the hospitalised patients with an established diagnosis of COVID-19 (n=4071).Results. This mathematical model, which includes 11 significant features, has been proposed for estimation of fatal outcomes in the Clinical Infectious Hospital named after S.P. Botkin. Some key features were not assessed in most hospitals according to accepted standards of care for COVID-19. So systematic analysis of factors affecting the course of disease in patients (n=2876) were conducted and «urea» and «total protein» were replaced with «sex» and «BMI». Modified algorithm demonstrated high sensitivity and specificity. Conclusion. This calculator is able to predict hospitalisation outcome with high accuracy in patients infected with different strains of SARS-CoV-2. This decision support system may be used for risk stratification and following correct patients routing.

1 January 2022 in Russian Journal of Preventive Medicine
Verified
Journal Article
Closed access
KGKsenia Golovatyuk
Ksenia Golovatyuk
TKTatiana Karonova
Tatiana Karonova
AMArina Mikhaylova
Arina Mikhaylova
DLD.I. Lagutina
D.I. Lagutina
ACA.T. Chernikova
A.T. Chernikova
ESE.V. Shlyakhto
E.V. Shlyakhto
В период пандемии новой коронавирусной инфекции сохраняется высокая распространенность недостаточности и дефицита витамина D, что является фактором, ухудшающим течение COVID-19. По результатам некоторых исследований, терапия колекальциферолом в дополнение к основной терапии COVID-19 ассоциирована с улучшением течения и прогноза заболевания. ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить влияние терапии колекальциферолом в дозе 100 000 МЕ на клинические и лабораторные показатели у больных со средним и тяжелым течением COVID-19, госпитализированных в инфекционный стационар. МАТЕРИАЛ И МЕТОДЫ В открытое одноцентровое интервенционное исследование включены 129 больных COVID-19, которые далее рандомизированы в две группы: больным 1-й группы (n=65) к основной терапии COVID-19 добавлен колекальциферол в суммарной дозе 100 000 МЕ; больные 2-й группы (n=64) колекальциферол не получали. РЕЗУЛЬТАТЫ На 9-й день госпитализации у пациентов 1-й группы (получавших колекальциферол) наблюдалось увеличение уровня 25(OH)D в сыворотке крови на 40,7%, в то время как у пациентов 2-й группы (без терапии колекальциферолом) отмечена отрицательная динамика этого показателя (p<0,001). Кроме того, у пациентов 1-й группы выявлены более высокие значения нейтрофилов и лимфоцитов (p=0,047; p=0,025), а также более низкий уровень С-реактивного белка (p=0,028). Обнаружена отрицательная связь между уровнем 25(OH)D и значением С-реактивного белка, а также между уровнем 25(OH)D и количеством койко-дней. ЗАКЛЮЧЕНИЕ Добавление колекальциферола в болюсной дозе к стандартной терапии COVID-19 оказывает положительное влияние на клиническое течение заболевания и уровень воспалительных маркеров.

8 July 2023 in Siberian Journal of Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
ВМВ. А. Малько
В. А. Малько
GBG. N. Bisaga
G. N. Bisaga
MTM. P. Topuzova
M. P. Topuzova
AVA. I. Vlasenko
A. I. Vlasenko
OSO. A. Shcherbakova
O. A. Shcherbakova
TATatiana M Alekseeva
Tatiana M Alekseeva
Actuality. Currently there are no long-term studies about the course of multiple sclerosis (MS) after coronavirus disease 2019 (COVID-19), in comparison with healthy volunteers who recovered from COVID-19 and patients with MS who didn’t have COVID-19.Aim: To study effect of COVID-19 on MS course.Material and Methods. We examined 39 patients with MS who recovered from COVID-19 (40.76 ± 11 years), 21 patients with MS who didn’t have COVID-19 (38.1 ± 12 years) and 33 healthy volunteers who recovered from COVID-19 (39.7 ± 10 years). We performed neurological examination and testing according to clinical and neuropsychological scales.Results. The majority of MS patients had a mild form of COVID-19 (22 people, 68.75%). Among the symptoms of COVID-19 in MS patients, headaches (12 people, 30.8% vs. 18 people, 54.5%) and chest pain (2 people, 5.1% vs. 9 people, 27.3%) were less common than in the control group of healthy volunteers. The duration of the disease, the age of onset, the average frequency of exacerbations, the use of disease modifying therapies, the result on clinical and neuropsychological scales did not show statistically significant differences between the two groups of patients with MS. The incidence of post-COVID syndrome in patients with MS was 79.48% and 88.44% in healthy volunteers. Among MS patients who had COVID-19, there were significantly more persons with a moderate decrease in the quality of life, higher fatigue scores compared to healthy volunteers, but less apathy compared to patients without COVID-19 with MS. The presence of vaccination reduced the risk of COVID-19 infection by 7.4 times in patients with MS.Conclusion. There was no significant effect of COVID-19 on patients with MS during short-term follow-up.

20 May 2023 in Translational Medicine
Verified
Journal Article
Open access
PDF file
AMArina Mikhaylova
Arina Mikhaylova
KGKsenia Golovatyuk
Ksenia Golovatyuk
DLD. I. Lagutina
D. I. Lagutina
AAAlena Andreeva
Alena Andreeva
EVElena Vasilyeva
Elena Vasilyeva
TKTatiana Karonova
Tatiana Karonova
Background. Recently, clinical benefits among COVID-19 patients, received vitamin D were demonstrated. Features of vitamin D metabolism in the acute period of COVID-19 remain unclear.Objective. To assess the level of 25(OH)D and 1,25(OH)2D in hospitalized COVID-19 patients and cholecalciferol effect on the vitamin D metabolites dynamic.Materials and methods. Group 1 (n = 22) patients received cholecalciferol bolus therapy at a total dose of 100,000 IU. Group 2 patients (n = 22) did not receive cholecalciferol supplementation. Serum 25(OH)D and 1,25(OH)2D levels were estimated for each group on the first and the ninth day of hospitalization.Results. On the ninth day of hospitalization 25(OH)D serum level demonstrated the 45.8 % rise in the Group 1, while in the Group 2 there was a decrease in the 25(OH)D level by 17.9%. At the same time, dynamic evaluation of the 1.25(OH)2D level did not show any differences between the groups, while pairwise comparison on the first and on the ninth days of hospitalization revealed an increase in the active metabolite concentration (p < 0.001) in both groups.Conclusion. Such vitamin D metabolism parameters in the acute period of COVID-19 may be associated with a 1α-hydroxylase activity alteration. Thus, 1.25(OH)2D serum level increase regardless of vitamin D status during the hospitalization could be explained by the COVID-19 course or concomitant corticosteroid medication.